Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Interstitial Lung Disease companies are AstraZeneca, CSL Behring, Syndax Pharmaceuticals, Taiho Pharmaceutical, GenKyoTex, Kadmon Pharmaceuticals, Novartis, Ark Biosciences, Roche, PureTech Health, Avalyn Pharma, Bristol-Myers Squibb, Insmed, Bayer, HEC Pharm, Prometheus Biosciences, Boehringer Ingelheim, Genentech, FibroGen, Reata Pharmaceuticals, Regend Therapeutics, Beijing Continent Pharmaceutical, Avalyn Pharmaceuticals, aTyr Pharma, Bristol-Myers Squibb, and AdAlta, and others.
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Interstitial Lung Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Interstitial Lung Disease Pipeline Analysis [https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report:

* Interstitial Lung Disease Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years.
* Interstitial Lung Disease companies working in the treatment market are AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others are developing therapies for the Interstitial Lung Disease treatment.
* Emerging Interstitial Lung Disease therapies such as AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others are expected to have a significant impact on the Interstitial Lung Disease market in the coming years.
* On March 2024, Boehringer Ingelheim announced a Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
* On April 2024, Boehringer Ingelheim announced a Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated With Nintedanib. The "INTENSE" Study.
* On January 2024, aTyr Pharma, Inc. announced a Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD).

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) encompasses a diverse group of disorders characterized by inflammation and scarring of lung tissue, leading to impaired gas exchange. Common symptoms include progressive dyspnea (shortness of breath), cough, and fatigue. ILD can be caused by various factors, including environmental exposures (such as asbestos or silica dust), autoimmune diseases (like rheumatoid arthritis or scleroderma), medications, and genetic predispositions. Diagnosis often involves a combination of clinical evaluation, imaging studies (such as high-resolution CT scans), pulmonary function tests, and sometimes lung biopsies. Treatment aims to alleviate symptoms, slow disease progression, and improve quality of life, and may include medications like corticosteroids, immunosuppressants, or antifibrotic agents. In some cases, lung transplantation may be considered for advanced disease. Prognosis varies depending on the specific type and severity of ILD, with some forms having a better outlook than others. Early detection and management are crucial in optimizing outcomes for patients with ILD.

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment- Interstitial Lung Disease Treatment Market [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Interstitial Lung Disease Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Oral
* Intravenous
* Subcutaneous

Interstitial Lung Disease Molecule Type

Interstitial Lung Disease Products have been categorized under various Molecule types, such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Interstitial Lung Disease Pipeline Therapeutics Assessment

* Interstitial Lung Disease Assessment by Product Type
* Interstitial Lung Disease By Stage and Product Type
* Interstitial Lung Disease Assessment by Route of Administration
* Interstitial Lung Disease By Stage and Route of Administration
* Interstitial Lung Disease Assessment by Molecule Type
* Interstitial Lung Disease by Stage and Molecule Type

DelveInsight's Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like-

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies- Interstitial Lung Disease Drugs and Therapies [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Interstitial Lung Disease Pipeline Analysis:

The Interstitial Lung Disease pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
* Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies- Interstitial Lung Disease Therapeutics Market [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of Interstitial Lung Disease Pipeline Drug Insight

* Coverage: Global
* Key Interstitial Lung Disease Companies: AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
* Key Interstitial Lung Disease Therapies: AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
* Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
* Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials - Interstitial Lung Disease Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Interstitial Lung Disease Report Introduction

2. Interstitial Lung Disease Executive Summary

3. Interstitial Lung Disease Overview

4. Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment

5. Interstitial Lung Disease Pipeline Therapeutics

6. Interstitial Lung Disease Late Stage Products (Phase II/III)

7. Interstitial Lung Disease Mid Stage Products (Phase II)

8. Interstitial Lung Disease Early Stage Products (Phase I)

9. Interstitial Lung Disease Preclinical Stage Products

10. Interstitial Lung Disease Therapeutics Assessment

11. Interstitial Lung Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Interstitial Lung Disease Companies

14. Interstitial Lung Disease Key Products

15. Interstitial Lung Disease Unmet Needs

16 . Interstitial Lung Disease Market Drivers and Barriers

17. Interstitial Lung Disease Future Perspectives and Conclusion

18. Interstitial Lung Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-lung-disease-clinical-trials-2024-fda-approvals-medication-pipeline-therapies-mechanism-of-action-route-of-administration-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services



This release was published on openPR.